In brief: SR One beats target for sophomore biotech fund

Fund II's limited partners include endowments, foundations, pharmaceutical companies, pension funds, sovereign wealth funds, and family offices.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this